LP-100 for AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
STAGE
Phase 2
DISEASE
Metastatic Castration-Resistant Prostate Cancer
TREATMENT
Irofulven + Prednisolone 10mg
LOCATION OF TRIAL
Rigshospitalet, Dept. of Oncology
Copenhagen, Denmark, 2100
This study seeks to evaluate the anti-tumor effect after treatment of Irofulven (LP-100) in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients. A drug response predictor (DRP®) biomarker in prostate cancer patients will identify patients likely to respond to and benefit from treatment with Irofulven.
For more information on the ongoing Phase 2 study of Irofulven in patients with mCRPC, please visit the study page.
